fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Tesla, Apple & Amazon Steal The Show Driving The Nasdaq Upward In Monday’s Session

By John F. Heerdink, Jr.

Tesla, Apple, and Amazon continued to shine brightly today as they closed up significantly while also driving the Nasdaq higher to a new all-time high of 11,829.84 prior to closing at 11,775.46 up .68%. It has truly been a show this year that many have had a ticket to the show and been making fortunes and many others have just been watching while simply munching on some popcorn. Which one are you?

Nevertheless, Tesla (TSLA) powered to a new all-time high of $500.02 prior to closing at $498.32/share up 12.57% in today’s session. Shares of Tesla seem to have no heights that it cannot achieve, at least for the moment as we have raced on its path towards its forward split…The same could be said about Apple (AAPL) which closed at $129.04/share up 3.39% as it also achieved a new all-time high of $131 after its forward split. At the risk of sounding like a broken record, Amazon (AMZN) jumped to $3,495 a new all-time high prior to closing at $3,450.96/share up 1.45%. However, Amazon did not trouble itself with a forward split, at least at this point.

The balance of the FAANG stocks dropped across the board as they ended as follows:  Facebook (FB) closed at $293.20/share down .16%, Netflix (NFLX) added 1.08% closing at $529.56/share & Alphabet (GOOG) closed at $1,634.18/share down .62%. 

The information technology sector moved up .4% on the back of the big tech stocks while the health care sector up .3%, and the utilities sector up .3% led all sectors rounded of the leaders today.

The balance of the indices all ended in the red today. The Dow 30 ended down .78% at 28,430.05. The S&P 500 also lost .22% closing at 3,500.31 & the Russell 2000 lost 1.04% closing at 1,561.88. 

The macroeconomic schedule did not produce anything of significance.

Gold closed at $1968(+3) while silver closed at $28.22/oz (+.64). North American silver and gold producer Hecla Mining Company (HL) closed at $6.02/share up 2.03% after recently establishing another new 52-week high of $6.79/share during intraday trading. HL’s 52-week low is $1.38.  Recently, Hecla reported 24% higher revenues on higher production and prices in Q2 2020. Cantor Fitzgerald Analyst Mike Kizak updated his coverage moving his Speculative Buy rating to a Buy rating and moving his target price to $7.25/share. North American silver producer First Majestic Silver (AG) closed at $12.45/share up 1.97% after recently establishing a new 52-week high of $14.57 recently. On Aug. 6th, AG reported that revenues had declined to $34.9M representing a decrease of 58% in response to COVID-19 and the decision to stockpile metal inventory in an effort to maximize future profits. 

Oil prices closed down .8% at $42.62/bbl. A few energy leaders closed as follows: Chevron (CVX) closed at $83.93/share down 1.99%, Exxon (XOM) closed at $39.94/share down 1.84% & highly leveraged Occidental Petroleum Corporation (OXY) closed at $12.74/share down 2.97%. Midstream player, Enterprise Products Partners (EPD), closed trading at $17.56/share down .73% and is currently sporting an attractive $1.78/share dividend or 10.06% while USA Corporation Partners, LP. (USAC), one of the nation’s largest independent providers of natural gas compression services, closed at $11.04/share down 2.04% while offering a $2.10/share (18.63%) dividend.

The 2-yr US treasury yield closed down 2 basis points at .13% while the 10-yr yield dropped 4 basis points to .69%. The U.S. Dollar Index strengthened to end at 93.03.

Here’s a couple of other equities that moved significantly higher today along with our stocks in view and what to expect from the macroeconomic schedule:

BIG MOVERS

  • Shares of peanut allergy treatment maker and the only approved drug for it, Aimmune Therapeutics (AIMT),  flew up 171%.59 to close a $34.22/share today as it was confirmed that Nestle will be acquiring AIMT for $2.6B. 
  • Shares of Aduro (ADRO) closed at $3.10/share up 10.32% after reaching $3.2174 intraday trading.
    On Aug. 18th, Chinook Therapeutics, Inc., a privately-held clinical-stage biotechnology company focused on the discovery, development, and commercialization of precision medicines for kidney diseases,  announced a $106 million private placement financing, with participation from new widely respected healthcare investors including EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech, and other top-tier healthcare investors. As part of the financing, Chinook’s existing investors, Versant Ventures, Apple Tree Partners and Samsara BioCapital, will purchase $25 million in Chinook common stock on the same terms as the new investors in lieu of their prior commitment to purchase convertible notes. The private placement closing is expected to occur immediately prior to the closing of the previously announced proposed merger between Chinook and Aduro Biotech, Inc. (NASDAQ: ADRO). Following the proposed merger closing, which is expected to occur in the second half of 2020, Aduro will be renamed Chinook Therapeutics, Inc., and is expected to trade on the Nasdaq Global Select Market under the ticker symbol “KDNY”. Closing of the private placement is subject to the satisfaction or waiver of all closing conditions for the proposed merger. Following the private placement financing, and upon closing of the merger, Chinook is expected to have at least $275 million in operating capital.

TOMORROW

The macroeconomic calendar will deliver the following reports:

  • The ISM Manufacturing Index for August
  • The Construction Spending report for July

WATCH LIST

Atossa Therapeutics (NASDAQ: ATOS) closed at $2.55/share after recently reaching a new 52-wk high of $5.08.

    • Interest continues to swell around both their breast cancer treatment and two COVID-19 drug programs.
    • ATOS’ stock has seen positive trading volatility this year and has moved up from $.76/share on significantly increasing trading volume and established a new 52-week high of $5.08/share on August 3rd when Atossa announced that it has received approval from the ethics committee to open a Phase 1 clinical study in Australia using Atossa’s proprietary drug candidate AT-301, to be administered by nasal spray. All necessary approvals have now been obtained and enrollment is expected to begin in the next 30 days.\

    • Recently, Atossa announced that it has enrolled and dosed the first cohort of healthy participants in the Phase 1 clinical study using its proprietary drug candidate AT-301, being administered by nasal spray. This group of 8 participants received a single dose of either AT-301A (placebo) or AT-301B (active). Steven Quay, M.D., Ph.D., Atossa’s President and CEO stated, “Advancing our COVID-19 drug candidates through clinical studies as quickly as possible is our highest priority. We are very encouraged by the high level of interest in this study and the speed at which we enrolled this first group of participants. Our novel nasal spray drug candidate is being developed to provide a unique protective mucosal barrier with anti-viral properties within the nasal cavity, hopefully leading to lower infectivity and reduced symptoms in COVID-19 patients. If this can slow virus proliferation sufficiently to allow the patient to mount a strong, natural immune response AT-301 could significantly impact the current public health options for controlling COVID-19. We look forward to quickly completing enrollment of all cohorts in this potentially important study.” Learn more.
    • Recently, Atossa announced its Q2 2020 financial results and gave a corporate update highlighting the following: 
      • Received approval from the Australian Human Research Ethics Committee (HREC) to open a Phase 1 clinical study in Australia using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. As of August 3, 2020, all necessary approvals were obtained and enrollment is expected to begin in the coming weeks.
      • Contracted with Avance Clinical Pty. Ltd. to conduct a clinical study of Atossa’s AT-301. Avance is a leading Australian clinical research organization and has successfully completed multiple clinical studies of Atossa’s proprietary Endoxifen.
      • Announced successful in vitro testing of both of Atossa’s COVID-19 therapies under development: AT-301 and AT-H201. The preliminary study results show that AT-301 and the components of AT-H201 inhibit SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which is the standard disease model used for initial screening of COVID-19 drug candidates.
      • Announced interim findings following 18 months of an Expanded Access (or “compassionate use”) single-patient study of Endoxifen. The patient in the study had no cancer recurrence and suffered no side effects. Endoxifen did not cause other safety and tolerability concerns in this patient.
      • Advanced product development programs with multiple key hires in clinical, regulatory, and chemistry manufacturing and controls. The hiring of these talented and highly accomplished individuals will help accelerate the advancement of Atossa’s development pipeline, which includes programs in breast cancer and COVID-19.
      • Completed sales of all available shares under Atossa’s at-the-market financing program with total gross proceeds to Atossa of $5 million through July 2020. As of June 30, 2020, the Company had approximately $7.5 million in cash and cash equivalents and with this program, they received an additional $4.3 million in July 2020.
    • We are seeking to see if ATOS successfully advances one or both COVID-19 programs by receiving IRB and FDA approval to move into the clinic.
  • Shares of Fate Therapeutics (FATE) closed at $34.40/share up 1.17%. Its 52-week range is $12.59 – $38.52/share.
    • Fate is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. 

    • On Aug. 19, Fate announced that Edward Dulac has been appointed Chief Financial Officer. Mr. Dulac comes to the Company from Celgene Corporation, where he most recently served as Vice President, Business Development & Strategy, and brings an extensive array of biopharmaceutical experience having served for over 20 years in positions in finance, business development, and product portfolio strategy.
    • On Aug. 5, Fate Reported Second Quarter 2020 Financial Results and Highlights Operational Progress ending the quarter with $533 Million in Cash & Short-term Investments. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “Early clinical data from our FT596 program are very encouraging, as we observed a partial response in a heavily-pretreated patient with refractory diffuse large B-cell lymphoma at the first dose level without any reported events of cytokine release syndrome, neurotoxicity or graft-versus-host disease. Additionally, the safety, tolerability, and immunogenicity data across our off-the-shelf NK cell programs continue to suggest that multiple doses of iPSC-derived NK cells can be administered to a patient without matching. We continue to be pleased with our pace of innovation, where the recent clearances of our IND applications by the FDA for FT538, the first-ever CRISPR-edited iPSC-derived cell therapy, and for FT819, the first-ever iPSC-derived CAR T-cell therapy, continue to demonstrate our unique ability to rapidly bring multiplexed engineered, off-the-shelf NK cell and T-cell cancer immunotherapies to patients. In addition, we successfully launched our Janssen collaboration with strong momentum, bringing together Janssen’s proprietary tumor-targeting antigen binders and our industry-leading iPSC product platform to develop novel off-the-shelf CAR NK and CAR T-cell immunotherapies for hematologic malignancies and solid tumors.”

    • July 14th, FATE announced that the Company entered into an exclusive license agreement with Baylor College of Medicine covering alloimmune defense receptors, a first-in-class approach that renders off-the-shelf allogeneic cell products resistant to host immune rejection. Preclinical studies published in the journal Nature Biotechnology (https://www.nature.com/articles/s41587-020-0601-5) demonstrate that allogeneic cells engineered with a novel alloimmune defense receptor (ADR) are protected from both T- and NK-cell mediated rejection, and provide proof-of-concept that ADR-expressing allogeneic cell therapies can durably persist in immunocompetent recipients.

    • On June 11th, FATE announced that it had closed an underwritten public offering of 7,108,796 shares of its common stock, which included 927,324 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $28.31 per share. Aggregate gross proceeds from this offering, including the exercise of the option, were approximately $201.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. 
  • Shares of NeuBase Therapeutics (NBSE) closed at $8.03/share up .75% today after recently reaching a new 52-week high recently of $11.78/share.

    • Chairman, CEO & Founder of NeuBase, Dietrich A. Stephan, Ph.D., presented at Tribe Public’s Webinar Presentation and Q&A Event that is scheduled to begin at 8 am pacific/11 am eastern Wednesday, August 26th, 2020.  During this complimentary, 30-minute event, Dietrich Stephan, Ph.D. will introduce the NeuBase’s next generation of gene silencing technology & the company’s progress with treatment candidates in Huntington’s Disease (HD) and Myotonic Dystrophy (DM1) and be available for Q&A. Here’s a link to the Tribe Public Youtube channel where you may watch the interview presentation.
    • NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders. NeuBase is continuing its progress towards developing treatment candidates in Huntington’s Disease (HD) and Myotonic Dystrophy (DM1.)
    • RBC Capital Markets recently initiated coverage of NBSE today with an Outperform, Speculative Risk rating & a $16 price target. 

    • NBSE recently reported its financial results for the three and nine-month periods ended June 30, 2020. Dietrich A. Stephan, Ph.D., chief executive officer of NeuBase stated, “We are pleased with the continued execution of our development programs during 2020. This includes the announcement in late-March of compelling data that firmly validates our platform as a viable fully synthetic approach to genetic medicine. Notably, these data confirm that our therapies penetrate into the brain when administered systemically – overcoming one of the grand challenges of drug delivery. PATrOL-enabled compounds can also access tissues throughout the entire body, opening our platform up to unexplored indications that have not previously been accessible by genetic medicine technologies. These positive pharmacokinetic and pharmacodynamic data-position our unique technology to output a vast pipeline of therapeutics to resolve innumerable human diseases. We anticipate presenting additional new data with respect to our ongoing progress in the fourth calendar quarter of this year. A key objective for our company shortly after the March data announcement was to strengthen our balance sheet in order to fully advance our strategies in HD and DM1, and build out our pipeline. This was accomplished in April with the closing of our oversubscribed capital raise of approximately $33.3 million in net proceeds that was led by fundamental healthcare investors and significantly increased our institutional shareholder base. We expect this to support our R&D and general corporate expenses into the second calendar quarter of 2022.”

  • Shares of Aduro (ADRO) closed at $3.10/share up 10.32% after reaching $3.2174 during intraday trading.
    • On Aug. 18th, Chinook Therapeutics, Inc., a privately-held clinical-stage biotechnology company focused on the discovery, development, and commercialization of precision medicines for kidney diseases,  announced a $106 million private placement financing, with participation from new widely respected healthcare investors including EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech, and other top-tier healthcare investors. As part of the financing, Chinook’s existing investors, Versant Ventures, Apple Tree Partners and Samsara BioCapital, will purchase $25 million in Chinook common stock on the same terms as the new investors in lieu of their prior commitment to purchase convertible notes. The private placement closing is expected to occur immediately prior to the closing of the previously announced proposed merger between Chinook and Aduro Biotech, Inc. (NASDAQ: ADRO). Following the proposed merger closing, which is expected to occur in the second half of 2020, Aduro will be renamed Chinook Therapeutics, Inc., and is expected to trade on the Nasdaq Global Select Market under the ticker symbol “KDNY”. Closing of the private placement is subject to the satisfaction or waiver of all closing conditions for the proposed merger. Following the private placement financing, and upon closing of the merger, Chinook is expected to have at least $275 million in operating capital.
    • On August 3rd, provided a business update and reported financial results for the second quarter ended June 30, 2020. Stephen T. Isaacs, chairman, president, and chief executive officer of Aduro stated, “The second quarter of 2020 was highlighted by the announcement of our planned merger with Chinook Therapeutics as well as significant progress in our BION-1301 program for IgA nephropathy (IgAN). We recently dosed the first IgAN patient with BION-1301 in Part 3 of our ongoing Phase 1 study and presented positive data from Parts 1 and 2 of this study in healthy volunteers at the 57th ERA-EDTA Virtual Congress. The data indicated BION-1301 was well-tolerated, had a half-life of approximately 33 days, achieved over 90% target engagement with a single 450 mg dose of BION-1301, and demonstrated dose-dependent and durable reductions in IgA and IgM levels, and to a lesser extent, IgG levels. We continue to enroll patients in our Phase 2 study of ADU-S100 in combination with pembrolizumab in squamous cell carcinoma of the head and neck and make progress on our cGAS-STING antagonist research collaboration with Lilly. We ended the second quarter of 2020 with a cash position of $186.1 million, which we believe will enable us to continue our ongoing STING and APRIL programs in the near-term and also meet our net cash requirements at the close of the merger with Chinook.” 
  • Shares of INVO Bioscience (INVO) closed at $4.30/share down 2.77% today.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated
    • INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. 
    • Recently, INVO announced financial results for the quarter ended June 30, 2020. Steve Shum, Chief Executive Officer of INVO Bioscience stated, “Despite the impact that COVID-19 has had in delaying fertility treatment for many around the world, we continue to make strong progress on our key goals to create commercialization agreements for our INVOcell solution. As we have been advancing our commercialization efforts outside the United States, industry leaders, as well as our internal team, have begun to recognize the expanded opportunity that exists through the creation of these joint ventures for developing dedicated, INVO-only centers in the U.S. and select markets around the world. The INVO center model also allows INVO Bioscience to participate in a greater share of the economics. Over the past year, we have had a number of conversations that started as standard distribution agreements that have evolved into potential joint venture agreements. We believe such partnerships, such as the one signed in India, will ultimately be mutually beneficial to achieving our goal to increase access to care and lower the cost of fertility treatment across the globe. Similar to the first quarter of 2020, the second quarter 2020 results were impacted by the COVID-19 virus outbreak which resulted in reduced product sales to Ferring. A majority of clinics curtailed their fertility services in connection with the lockdowns that occurred. Many of the clinics have since resumed operations, albeit at a measured pace. As a result, and along with Ferring’s required annual minimums, we expect to experience stronger sales in the second half of 2020. We also believe that new guidelines that requiring limiting interactions and social distancing at most clinics could favor accelerated adoption of our technology, which allows for a more streamlined cycle approach with fewer patient visits and reduced lab requirements and resources.”

    • I am expecting to see the company push forward with new market supportive initiatives and awareness of their INVOcell product in the back half of 2020 that may result in further adoption in the US clinics and establishing new joint ventures, partners, and distributors throughout the world.

    • Tiny Float – INVO has ~7.89 million shares outstanding and with ~+15% insider ownership the share float is tight and recently confirmed that the company raised ~$3.5M.

  • Rocket Companies, Inc. (RKT) recently went public at $18/share with a host of big wirehouses and closed trading at $28/share today.
    • They are due to report earnings on Tuesday night after the close and I would expect that this report might be favorable in this rapid refinancing low-interest-rate market.
    • It will also be 27 days since its IPO on Tuesday and I would expect that the analysts will begin to roll out their Buy recommendations as they will be released to do so soon thereafter with a fresh set of financials.

Economic Reports

  • On Monday, we did not receive any significant reports.
  • On Tuesday, we received the on a negative note, the Conference Board’s Consumer Confidence Index report which showed a drop to 84.8 in August.  However, the New home sales report jumped 13.9% month/month in July to a seasonally adjusted annual rate of 901k. The S&P Case-Shiller Home Price Index report for June confirmed a move higher by 3.5% & the FHFA Housing Price Index report for August confirmed a rise by .9%.
  • On Wednesday, the new orders for durable goods report confirmed a rise by 11.2% month/month in July & when you exclude transportation, new orders climbed 2.4% month/month. The weekly MBA Mortgage Applications Index report confirmed a drop of 6.5%.
  • On Thursday, the initial jobless claims report for the week ending August 22 confirmed a drop by 98k to 1.006M, while continuing claims for the week ending August 15 dropped by 223k to 14.535M. We also received the second estimate for Q2 GDP which showed output dropped at an annualized rate of 31.7% while the GDP price index was down 2%.

Investing & Inspiration

“Liquidity is only there when you don’t need it.” -Old Proverb

“If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson

“Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel

“In investing, what is comfortable is rarely profitable.” – Robert Arnott

“Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger

“The entrance strategy is actually more important than the exit strategy.” – Edward Lampert

“The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis

“It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton

“An investment in knowledge pays the best interest.” – Benjamin Franklin.

I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates

“Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman

“The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy

“If all the economists were laid end to end, they’d never reach a conclusion.
-George Bernard Shaw

“The riskiest thing we can do is just maintain the status quo.
I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” Bob Iger, Ceo of Disney

“There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota

“Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”

“As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer

“I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban

Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner

“The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru

“The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher

“I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis

“The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton

“Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos: